Positive Late-Stage Data Reported for Tiotropium in Asthma Patients
Treatment improves lung function in mild, moderate, and severe disease
Positive data from several phase III studies of tiotropium (Boehringer Ingelheim) delivered via the Respimat inhaler in patients with mild, moderate, or severe asthma patients have been presented at the 2014 American Academy of Allergy, Asthma & Immunology annual meeting in San Diego.
Tiotropium is being studied to determine its efficacy and safety in treating asthma patients and is not currently approved for this indication.
Results from the phase III GraziaTinA-asthma trial showed that tiotropium, delivered via the Respimat inhaler, improved lung function response, as measured by the forced expiratory volume in 1 second (FEV1), in patients with mild asthma who remained symptomatic while receiving low-dose inhaled corticosteroid (ICS) treatment.
Further, a pre-specified subset of data from a pair of phase III MezzoTinA-asthma trials showed that the addition of once-daily tiotropium reduced airflow obstruction independently of allergic status, as measured by TH2 phenotype biomarkers,, in patients with moderate asthma who remained symptomatic while receiving medium-dose ICS therapy.
Another subset of data found that the addition of once-daily tiotropium in two phase III PrimoTinA-asthma trials improved lung function responses independently of concomitant use of a leukotriene receptor antagonist in patients with severe asthma.
Source: Boehringer Ingelheim; March 1, 2014.